rVAR2 binds with the distinct oncofetal chondroitin sulfate that makes rVAR2 a potential ideal carrier for anti-cancer drug delivery; Activation of NK cell, DC, CD8+ T cell; Suppressed the levels of angiogenic factors (VEGF, MMP9, IGF); Reduce the numbers of MDSC and Treg through CCL17/22-CCR4 pathway. The gene discussed is CCL17; the disease is cancer.